AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy
Afinitor International Website | For Healthcare Professionals Outside the U.S. | US Residents
Learn About Prescribing AFINITOR®
In advanced renal cell carcinoma, after disease progression or after VEGF**-targeted therapy: AFINITOR — The once-daily, oral therapy
Simple dosing regimen is convenient for patients
- AFINITOR is available in 10-mg or 5-mg once-daily tablets
- Once daily oral administration allows for continuous mTOR inhibition
AFINITOR is easy to administer
- Dosage is the same regardless of age, gender, body weight or renal function
- No premedication is required
- Take once daily at the same time every day, consistently either with or without food
Flexible dosing strategies
- Dose may be reduced to 5 mg daily or interrupted as appropriate to manage severe and/or intolerable adverse reactions
Packaging shown may vary from the AFINITOR package available in your country
**VEGF: vascular endothelial growth factor
